Congrats to Lizzo for winning this year’s Elevate Prize Catalyst Award! We were proud to have P4AD’s Merith Basey representing patients at the #MakeGoodFamous summit this week. It’s About Damn Time [to lower drug prices]!
Welcome To The Week In Review.
1. Momentum For PBM Reform
Pharmacy Benefit Managers (PBMs) are continuing to face scrutiny from Congress, federal agencies, employers, and organizations representing patients. Following last week’s win in the Senate HELP Committee, the House Energy and Commerce Subcommittee on Health passed a package of bipartisan bills on Wednesday that include price transparency and PBM legislation. “PBM measures have particular momentum,“ Axios reported. “Versions of transparency and PBM bills could end up in a broader legislative package later this year.” That same day, the House Ways and Means Subcommittee on Health held a hearing that also looked into how PBMs are a factor in driving up costs for patients. “The rebates that are negotiated by PBMs are completely confidential,” Dr. Benjamin Rome, health policy researcher at Harvard Medical School, said. “Shining some light on the prices that are actually being paid and making it clear where the problems are in the PBM business model would be extraordinarily helpful.” The Federal Trade Commission (FTC) continued its scrutiny of PBM practices — the agency ramped up its ongoing investigation into PBMs this week by issuing orders to two group purchasing organizations (which negotiate drug rebates on behalf of PBMs) to provide details on their shady business practices. Employers spoke up on this issue as well — the Purchaser Business Group on Health (PBGH) outlined four keyreforms regarding PBMs: eliminating spread pricing, instituting radical transparency, ensuring 100 percent of rebates are passed to patients, and making PBMs fiduciaries. “The fact that PBMs limit patient access to life-saving prescription drugs and strip doctors of treatment options is unconscionable. PBMs are supposed to lower drug costs and increase access to vital medicines,” wrote David Reeves, executive director of the Alabama Kidney Foundation, in an op-ed. “Congress has taken steps to reduce harmful PBM business practices, but more must be done.” Well said, David — looks like momentum is growing to finally crack down on PBM practices. — (House Energy and Commerce Committee, Axios, House Ways and Means Committee, Fierce Healthcare, Federal Trade Commission, Fierce Healthcare, Alabama Political Reporter)
2. Scamming and Cheating: Big Pharma’s Middle Name
More egregious evidence this week of Big Pharma shamelessly scamming patients and taxpayers. First up: tax gaming. The drug industry gets most of its revenue from drug sales in the U.S., but avoids paying domestic taxes by “assigning patents and other forms of intellectual property” to other countries overseas. Senator Ron Wyden explained that this tactic “allows these hugely profitable companies to pay tax rates lower than many middle-class Americans,” who are also left to pay nearly three times what other wealthy nations pay for the same prescription drugs. Second: antitrust law violations. The Initiative for Medicines, Access & Knowledge (I-MAK) and the American Economic Liberties Project released a groundbreaking new report that found Big Pharma’s antitrust violations cost American families and government health programs an additional $40 billion in 2019 alone. “The patent system is at the root of enabling many of the antitrust violations we identified and which are leading to higher drug prices,” said Tahir Amin, an executive director of I-MAK. Thankfully, the Federal Trade Commission (FTC) stepped up to curb anticompetitive drug company behavior that harms patients and keeps prices high. This week, the agency filed a lawsuit to stop Amgen Inc. from acquiring Horizon Therapeutics – a move that would prevent generics from coming to market. The lawsuit sent a clear message to the industry: “The FTC won’t hesitate to challenge mergers that enable pharmaceutical conglomerates to entrench their monopolies at the expense of consumers and fair competition.” Messaged received: Amgen immediately agreed not to quickly close on its $27.8 billion acquisition. We must continue to crack down on Big Pharma’s scamming and cheating and pass laws that fix our rigged patent system, ensure the industry pays its fair share in taxes, and hold drug companies accountable for antitrust violations. — (New York Times, Fierce Pharma, American Economic Liberties Project and Initiative for Medicines, Access, & Knowledge (I-MAK), Common Dreams, Federal Trade Commission, Reuters)
3. Numbers Don’t Lie: Drug Prices Are Notoriously High
Reports and news coverage this week confirm what we already know — drug prices and the cost of medical treatments are outrageously high and patients are suffering as a result. A new study published in JAMA found that 1 in 5 adults over the age of 65 “either skipped, delayed, or took less medication than was prescribed, or took someone else’s medication last year” because of high drug costs. 8.5 percent of participants in the study said they had to forego basic needs — like gas and groceries — because of high drug costs, and almost 5 percent said they went into debt to get their medications. Patients who live with breast cancer — the most expensive cancer, as reported by the National Cancer Institute (NCI) — face treatment costs ranging between $20,000 to $100,000. KFF looked into Leqembi, a new drug to treat Alzheimer’s disease currently in clinical trials, which carries a list price of $26,500 — an outrageous amount of money. People on Medicare taking the drug could see more than $5,000 a year in out-of-pocket costs if the Food and Drug Administration (FDA) grants full approval. “Even with Medicare coverage … Leqembi could be beyond the reach of many people with Medicare, whose median income is around $30,000 per person,” explained KFF. “… the high cost of treatment could raise equity concerns if it means Black and Hispanic beneficiaries are less likely to gain access to this treatment because they can’t afford it.” We need a system that ensures patients can access drugs at prices they can afford — both right now and for new, innovative treatments on the horizon. We will keep fighting until all patients can afford their medicines. (NBC News, Health Central, KFF)
BONUS: P4AD’s Merith Basey went head-to-head with pharma executives this week at the Financial Times US Pharma and Biotech Summit! During a panel discussion on the Inflation Reduction Act, Merith debunked the industry’s false claims about innovation, explained how the new law will help patients who are struggling with high drug prices, and set the record straight on the role of taxpayer investment in R&D. Thanks for advocating for people over profit, Merith!
Have a great weekend, everyone!
Welcome To The Week In Review.
1. Critical Win: Senate HELP Passes Bipartisan Package
On Thursday, the Senate Health, Education, Labor and Pensions (HELP) Committee voted to advance a major package of bipartisan bills to lower drug prices for patients. This legislation would promote transparency, competition, and accountability as well as curb anticompetitive behavior committed by pharmaceutical corporations and Pharmacy Benefit Managers (PBMs). “This package of bills represents a significant step towards restoring accountability to the U.S. drug price system so that it prioritizes patients, rather than the bottom line of the pharma and PBM industries,” P4AD’s Merith Basey remarked. The markup was preceded by a HELP hearing the previous day, where the big three insulin CEOs and the big three Pharmacy Benefit Managers (PBMs) were grilled by senators from both sides of the aisle on high drug prices and industry profits. Charmain Sanders summarized: “If somebody in the real world is watching this hearing, they’ve heard every single person from the drug companies and from the PBMs say, ‘We are working tirelessly to lower the cost of prescription drugs…’ And yet, at the end of the day, 1.3 million Americans are rationing their insulin.” Patientsknow that both the pharma and the PBM industries are to blame for high drug prices and that both need reform. Senate Majority Leader Schumer, it’s time to bring these bills to the floor for a vote as soon as possible. — (P4ADNow, The Hill, Bloomberg, Vox, The Hill, KFF, Politico, The Gander, Fox8)
2. Pushing Back On Big Pharma Lies
Big Pharma and its allies are continuing to spread false claims about the Inflation Reduction Act. The House Ways and Means Subcommittee on Health held a hearing to examine “Policies that Inhibit Innovation and Patient Access” – but patients know better than to believe the fearmongering of the industry and its allies. “We can achieve balance to have innovative, safe, and effective drugs at prices all people can afford. The Inflation Reduction Act is an example of policy that takes us in the right direction,” P4ADNow’s David Mitchell submitted in written testimony. At the hearing, Harvard Medical School professor and researcher Aaron Kesselheim explained how taxpayer funded research for the COVID vaccine “almost completely derisk[s] the investment for manufacturers.” And Rep. Lloyd Doggett fiercely set the record straight: “Patients come first. It is their health and livelihood — not drug prices — which must be non negotiable. Unaffordability and inaccessibility are not the unavoidable side effects of innovation.” David Mitchell also pushed back on Big Pharma’s lie that the drug price reforms in the Inflation Reduction Act hurt innovation and economically disadvantage small molecule drugs compared to biologics. “The Inflation Reduction Act actually contains more protections for small-molecule medicines because it narrows the difference in years of protection from Medicare negotiation between biologics and small molecules to 4 years,” he wrote in a letter to the editor. “That’s good news for patients like me who rely on both small-molecule drugs and biologics to stay alive.” — (P4ADNow, Endpoints, NY Daily News)
3. Applauding The Inflation Reduction Act
Members of Congress continue to spread the word about how the Inflation Reduction Act is helping patients across the county. “If you’re on Medicare, you won’t pay more than $2,000 a year out of pocket for drugs and keep in place that $35 limit on what a dose of insulin costs, because that’s been increased just for profit for corporations, not because it needs to be to cover the cost of production,” Congresswoman Dina Titus said at an event where she received an award for her continuous support for seniors. Senator Debbie Stabenowspoke with AARP this week about the new drug price law: “In the Inflation Reduction Act we did a number of things – one, finally we have given Medicare the authority to negotiate the best price.” She continued, “If the drug company raises the price of medicine faster than inflation, they are going to have to give a rebate back.” Patients in Nevada, Michigan, and across the country will continue to feel relief in drug prices thanks to the new law. — (KSNVABC4 West Michigan)
Have a great weekend, everyone!
WASHINGTON, D.C. — The following statement was issued by Merith Basey, executive director of Patients For Affordable Drugs Now, in response to the Senate Health, Education, Labor and Pensions (HELP) Committee’s vote to advance a package of bipartisan bills. This legislation would lower drug prices by promoting transparency, competition, and accountability and curbing anticompetitive behavior committed by pharmaceutical corporations and Pharmacy Benefit Managers (PBMs):
“On behalf of patients across the U.S., we applaud Chairman Sanders, Ranking Member Cassidy, and the members of the Senate HELP Committee for passing bipartisan legislation to increase competition, incentivize innovation, require transparency, and crack down on opaque practices of Pharmacy Benefit Managers (PBMs). This package of bills represents a significant step towards restoring accountability to the U.S. drug price system so that it prioritizes patients, rather than the bottom line of the pharma and PBM industries.
“We call on Senate Majority Leader Schumer to bring these bills to the floor for a vote as soon as possible. It’s high time we restore balance to our rigged drug price system – patients can’t wait!”
###
Background:
A recording of this morning’s Senate HELP Committee markup can be watched here.
The legislative package includes the following pieces of drug pricing legislation:
The Ensuring Timely Access to Generics Act of 2023 (S. 1067), led by Senators Shaheen (D-NH), Collins (R-ME), Bennet (D-CO), Rubio (R-FL), Baldwin (D-WI), and Braun (R-IN) would increase competition for generic drugs by cracking down on abuse of the Food and Drug Administration’s (FDA) citizen petition process. P4ADNow has beenadvocatingforreforms to the citizen petition process since 2018.
The Retaining Access and Restoring Exclusivity (RARE) Act (S. 1214), introduced by Senators Baldwin (D-WI) and Braun (R-IN), would close a loophole in the FDA’s orphan drug approval process and restore incentives to develop drugs for rare diseases. The RARE Act is endorsed by P4ADNow.
The Increasing Transparency in Generic Drug Applications Act (S. 775), led by Senators Hassan (D-NH) and Paul (R-KY) will speed more affordable generic drugs to market by giving the FDA the authority to provide specific information on inactive ingredients and drug concentration levels to generic applicants working to come to market. S. 775 is endorsed by P4ADNow.
The Fair Accountability and Innovative Research (FAIR) Drug Pricing Act (S. 935), led by Senators Baldwin (D-WI), Braun (R-IN), and Smith (D-MN) requires drug companies to provide notice and justification reports on certain prescription drug price increases. P4ADNow has endorsed the FAIR Act in three consecutive congresses.
The Pharmacy Benefit Manager Reform Act (S. 1339), led by Chairman Sanders (I-VT) and Ranking Member Cassidy (R-LA), bans spread pricing by Pharmacy Benefit Managers (PBMs), requires that rebates be passed through to insurance companies, and increases transparency into the opaque practices of PBMs.
The Expanding Access to Low-Cost Generics Act of 2023 (S. 1114), led by Senators Smith (D-MN) and Braun (R-IN), restores incentives to bring generic products to market in a timely manner by addressing anticompetitive “parking” behavior.
An amendment led by Senators Braun (R-IN) and Marshall (R-KS), that would require the Department of Labor to conduct a study on what the impact would be if PBMs had fiduciary duties to the health plans and employers they serve.
Last week, more than 40 groups sent a letter to every member of the Senate to urge passage of legislation to lower drug prices by strengthening the U.S. patent and regulatory systems, spurring competition, and addressing opaque practices of PBMs to ensure they are serving patients and consumers first.
This bipartisan package can now receive votes on the Senate floor. Today’s markup follows the passage of five bipartisan bills out of the Senate Judiciary Committee in February.
The following written testimony was submitted on behalf of David Mitchell, founder and president of Patients For Affordable Drugs Now, ahead of the House Ways and Means Health Subcommittee hearing on “Examining Policies that Inhibit Innovation and Patient Access”:
A lovely recognition from Washingtonian (and on his 73rd birthday!?) of our founder David Mitchell who was an “integral player in forcing the prescription-drug provision into the Inflation Reduction Act.” Congrats, David! Well deserved.
Welcome To The Week In Review.
1. Dozens Of Organizations Pressure Senate To Lower Drug Prices
Over 40 organizations sent a letter to the Senate urging them to advance a package of bipartisan legislation this year to lower drug prices through increased competition, transparency, and accountability. The organizations — representing patients, consumers, seniors, churches, students, and disease advocacy groups — united in insisting senators focus on strengthening the U.S. patent and regulatory systems, increasing competition, and addressing the shady practices of Pharmacy Benefit Managers (PBMs) to ensure they are serving patients first. “There is bipartisan support in Congress to pass common-sense reforms that will further improve the U.S. drug pricing system and lower prices for more patients,” said P4ADNow’s David Mitchell. AARP, who co-led the letter with P4ADNow, emphasized: “More than 80 percent of voters across party lines want federal agencies such as the Food and Drug Administration to encourage more competition in the prescription drug marketplace.” There is clearly bipartisan momentum to pass meaningful drug price reforms this year. Next week, the Senate Health, Education, Labor and Pensions (HELP) Committee will hold two hearings — one with CEOs from insulin manufacturers and PBMs and another to mark up bipartisan legislation to close loopholes in the regulatory system and accelerate generic competition. We urge the 118th Senate to keep up the good work and prioritize advancing a package of bills to the Senate floor to lower drug prices for patients. — (P4ADNow, AARP, Bloomberg)
2. More Inflation Reduction Act Savings For Patients — “It’s huge.”
Patients are seeing savings thanks to the drug price reforms in the Inflation Reduction Act. More than 37,000 Tennesseans will benefit from the $2,000 out-of-pocket cost cap when it takes effect in 2025 and many West Virginians on Medicare are better able “to buy groceries, and pay their rent and utility bills” due to the $35 monthly insulin copay caps. Members of the Biden administration continued to share how the new historic drug price law is helping patients. “Well, as you know, we pay the highest drug cost of any advanced nation in the world … but now we reduced the cost of insulin from hundreds of dollars a month to $35 a month — for anyone on Medicare,” remarked President Biden at a Democratic National Committee (DNC) reception. Vice President Kamala Harris echoed similar sentiments, saying “we were able to cap the cost of insulin for seniors at $35 a month. It’s huge.” Department of Health and Human Services (HHS) Secretary Xavier Becerra and Congresswoman Jennifer Wexton toured a senior living center in Virginia and touted the legislation, which will save Virginians who receive insulin through Medicare more than $500 per year. Becerra laid out the sizable impact of the new drug price law for American families: “The Inflation Reduction Act has now made it possible for families to be able to afford a lot of that health care that sometimes can cost a lot of money.” — (Citizen Tribune, Public News Service, The White House, The White House, Inside Nova)
3. Big Pharma’s Greed Knows No End
New numbers show that Big Pharma unsurprisingly has been cashing out on advertisements, lobbying spending, patent abuses, and huge CEO salaries. The pharma industry spent nearly $8.1 billion on ads in 2022 while patients struggled to afford life-saving medications. Health industry lobbying far outpaced any other sector with The Pharmaceutical Research and Manufacturers of America (PhRMA) spending over $8 million in the first quarter of the year. Big Pharma CEOs took home eye-bulging amounts of pay: In 2022, Biogen CEO Chris Viehbacher was compensated $30.5 million and Moderna CEO Stéphane Bancel made nearly $400 million from stock options (not to mention he raised his salary by 50% to $1.5 million). Meanwhile, Moderna announced this week that its updated mRNA COVID-19 vaccine will be priced up to $130 per shot — looks like Bancel plans to continue profiting off the backs of taxpayer funded research. Speaking of taxpayer dollars, a new study in Health Affairs shows that the U.S. government spent $143 million towards development and clinical testing of Truvada, the first approved HIV prevention pill. Yet drugmaker Gilead has hiked the price by more than 40% and made as much as $3 billion annually off the taxpayer-supported drug. Gilead’s trial — in which the federal government is suing Gilead for infringement on government-owned patents — began this week. While drug companies claim that high drug prices are needed to justify research and development, the truth is they simply want to line their coffers with more and more profit. (Fierce Pharma, Open Secrets,Fierce Pharma, Washington Post, Ars Technica, Health Affairs, Endpoints)
BONUS: Florida patient advocate Xanadu Roque eloquently speaks about her experience growing up with type 1 diabetes, issues with accessing insulin in her community, and the growing pressure from advocates to lower insulin prices. Checkitout!
Have a great weekend, everyone!
Groups Representing Patients, Consumers, Seniors, Churches, Students, And Disease Advocacy Groups Align On Action To Lower Drug Prices
WASHINGTON, D.C. — Patients For Affordable Drugs Now and AARP, along with 39 organizations representing patients, consumers, seniors, churches, students, and disease advocacy groups sent a letter to all members of the 118th Senate urging them to advance legislation to strengthen the U.S. patent and regulatory systems, spur competition, address opaque practices of Pharmacy Benefit Managers (PBMs) to ensure they are serving patients and consumers first, and lower drug prices for millions.
“There is bipartisan support in Congress to pass common-sense reforms that will further improve the U.S. drug pricing system and lower prices for more patients,” said David Mitchell, a patient with incurable blood cancer whose drugs carry a list price of more than $900,000 per year and founder of Patients For Affordable Drugs Now. “Too many drug prices are still far too high for too many people. We must continue to push until all people can afford their medicines.”
The letter was sent ahead of the HELP Committee markup on four bipartisan bills to close loopholes in the regulatory system and accelerate generic competition. The letter follows the February passage in the Senate Judiciary Committee of five bipartisan bills to reform the patent system and improve competition. This spring, the Senate is expected to assemble a health package that includes these critical bills.
“One in four people in the United States has difficulty affording medications,” the letter reads. “We are grateful to see movement on critical issues such as access to health care and prescription drugs. We urge the Senate to immediately act on legislation to lower drug prices through increased competition, transparency, and accountability.”
Read the full letter and list of signers here and below.
May 1, 2023
Dear Members of the 118th Senate,
As organizations representing patients, consumers, seniors, churches, students, and disease advocacy groups we are grateful to see movement on critical issues such as access to health care and prescription drugs. We urge the Senate to immediately act on legislation to lower drug prices through increased competition, transparency, and accountability.
One in four people in the United States (U.S.) has difficulty affording medications, including an estimated 3.5 million adults age 65 and older. People of color are disproportionately harmed by high drug prices, which contribute to the fact that uninsured Latinos and Black Americans use 10-40% fewer medications than their White counterparts. Further, among adults 65 and older, Latino and Black adults are roughly 1.5 times more likely to have trouble affording needed medications than Non-Latino White adults and 2 times as likely not to get needed prescriptions due to cost.
Drug companies in the U.S. have unlimited, unilateral pricing power during time-limited monopoly periods awarded by the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA.) Many big drug companies prolong these monopoly periods by employing anti-competitive tactics exploiting loopholes in our patent laws to block competition, while patients, employers, and taxpayers are left paying prices that are up to four times what other wealthy nations pay for the exact same brand name drugs.
Downstream in the supply chain, three large pharmacy benefit managers (PBMs) dominate roughly 80 percent of the drug market. PBMs argue that this concentrated market share allows them to negotiate effectively with drug companies. However, there are growing concerns that some opaque business practices of PBMs may be contributing to higher prescription drug costs for consumers.
This spring, the Senate has the opportunity to advance a package of bipartisan bills that will strengthen our patent and regulatory systems, spur competition, address practices of PBMs to ensure they are serving patients and consumers first, and lower drug prices for millions. We urge the Senate to ensure inclusion of bills to:
Increase Competition: Brand-name pharmaceutical companies engage in tactics aimed at preventing competition that harm consumers and their health; these behaviors include paying generic manufacturers to delay entering the market or making trivial, non-innovative changes to medicines in an effort to avoid competition from a prospective generic. There are bipartisan bills in the Senate that strengthen the patent system by banning anti-competitive tactics such as “pay-for-delay” deals and product hopping tactics. These bills have passed House and Senate Judiciary Committees on strong bipartisan votes in the past two Congresses. Bipartisan legislation under consideration by the Senate Health, Education, Labor and Pensions (HELP) Committee can further spur competition by preventing big drug companies from manipulating FDA processes in order to thwart competitors. Beyond broad Senate support, these reforms enjoy the support of the American people. More than 80% of voters across party lines want federal agencies such as the USPTO and the FDA to encourage greater competition in the prescription drug marketplace.
Promote Transparency: By design, the U.S. drug price system is complex and convoluted, making it difficult for policymakers, patients, and health care providers to find straightforward information about drug costs. The Senate must advance bipartisan legislation that requires drug companies to disclose and justify high prices.
Hold Pharmacy Benefit Managers Accountable: Consolidation within the pharmacy benefit manager sector has given PBMs a great deal of negotiating power. However, the complicated nature of the drug supply chain can make it difficult for patients, employers, and policymakers to determine when PBM business practices are in the best interests of patients. Bipartisan legislation could require more transparency and accountability to better ensure PBMs act in the best interests of patients and consumers.
Together these reforms take vital steps to promote competition, transparency, and accountability that will lower drug prices for patients, payers, and taxpayers, including the constituencies we represent. On behalf of these constituencies, we urge the Senate to act immediately to advance a package with these reforms.
Signed:
AARP ACA Consumer Advocacy American Medical Student Association (AMSA) Americans for Democratic Action, Southern California Arkansas Community Organizations Beta Cell Action Campaign for a Family Friendly Economy (CFFE) Center for Health & Democracy Center for Medicare Advocacy Church World Service Committee to Protect Health Care Community Catalyst Consumer Action Families USA Florida Alliance for Healthcare Value Generation Patient Health Care Voices Initiative for Medicines, Access & Knowledge (I-MAK) Interfaith Center on Corporate Responsibility Lower Drug Prices Now (LDPN) Medicare Rights Center MomsRising National Committee to Preserve Social Security and Medicare National Multiple Sclerosis Society Oregonizers Patients For Affordable Drugs Now Prescription Justice Protect Our Care Public Citizen Rise Up WV Salud y Farmácos Social Security Works SPACEs in Action T1International Tennessee Health Care Campaign U.S. PIRG Unity Fellowship of Christ Church-NYC Universities Allied for Essential Medicines (UAEM) VOCAL-NY West Virginians for Affordable Health Care WV Citizen Action Group
###
Looks like PhRMA has a gold check on Twitter now, which costs $1,000 per month — an easy price for corporations to pay off the back of patients when drugs like Sovaldi are priced at $1,000 per pill.
Welcome To The Week In Review.
1. Up Next: Drug Price Reforms On The Horizon
Congress is back in session and reforms to rein in high drug prices are top of mind in both chambers. In the Senate, Finance Committee Chairman Ron Wyden and Ranking Member Mike Crapo released a bipartisanframework for legislation to target Pharmacy Benefit Managers (PBMs) that “unfairly inflate the prices patients and government programs pay for prescription drugs.” The Senate Health, Education, Labor and Pensions (HELP) Committee plans to hold its markup next week to markup legislation focused on accelerating generic drug entry, closing regulatory loopholes used by big drug companies to block competition, and reforming specific practices of PBMs. Chairman Bernie Sanders also plans to question executives of top insulin makers and PBMs at another hearing on May 10. In the House, the Energy and Commerce Committee will hold a hearing next Wednesday on transparency, competition, and PBM reform. This Congress brings a real opportunity to advance a package of bipartisan bills that will strengthen our patent and regulatory systems, spur competition, address practices of PBMs to ensure they are serving patients and consumers first, and lower drug prices for millions. Let’s do this, Congress. — (Senate Finance Committee, Endpoints, Politico, Politico, Axios, PIRG)
2. The Inflation Reduction Act Keeps Helping Patients
Patients on Medicare are saving on drug prices thanks to the reforms in the Inflation Reduction Act – and members of Congress continue to spread the word. In an op-ed, Senator Tammy Baldwin reminded her constituents that “we took on the drug industry again and we won.” She explained that “we beat Big Pharma, passing a law to lower drug prices and cap insulin costs at $35 a month for our seniors.” Senator Sherrod Brown agreed that the insulin copay caps are making a huge difference for patients in his community. He shared that Ohioans on Medicare are saving $500 a year from the new provision. “The Inflation Reduction Act finally took on the drug companies and lowered drug prices for Americans on Medicare,” Senator Brown wrote. ? — (The Madison Times, The Ironton Tribune)
3. Big Pharma Myth Busters
Big Pharma peddled lies this week about Medicare negotiation in the Inflation Reduction Act. The Pharmaceutical Research and Manufacturers of America (PhRMA) — who has been crying wolf for decades about the need for high drug prices to cover costs of research and development (R&D) — is shifting tactics now that the Centers for Medicare & Medicaid Services (CMS) is requiring drug companies to justify R&D costs as part of the negotiation process. The reality? “Drug companies know that when we see behind the curtain, the true costs of R&D won’t justify their high prices,” P4AD’s David Mitchell told STAT. CMS Administrator Chiquita Brooks-LaSure explained: “By considering factors such as clinical benefit and unmet medical need, drug price negotiation intends to increase access to innovative treatments for people with Medicare.” According to a new study published in The Journal of the American Medical Association (JAMA), 27 of Medicare’s top-selling drugs — which account for nearly $20 billion in Medicare spending — actually have “little or no therapeutic benefit over therapeutic alternatives”! Thankfully, Medicare’s new negotiation authority ensures the program can examine whether a drug is truly innovative, which will better serve patients. We won’t be fooled by Big Pharma’s big lies — we know the Inflation Reduction Act will rein in prescription drug prices for patients who need this long-awaited relief. — (STAT, Fierce Healthcare, JAMA)
BONUS: Check out patient advocate Kat Schroeder’s interview in Virginia Dogwood, where she shares her personal experience with rationing insulin due to high prices and comments on the power of advocacy to finally see the prices of insulin lowered. Thanks for your wise words, Kat!
Have a great weekend, everyone!
Welcome To The Week In Review.
1. HELP Is On The Way
The Senate Health, Education, Labor and Pensions (HELP) Committee is continuing to gather input in advance of their now-delayed markup on drug price legislation. The markup is expected to examine legislation focused on spurring generic drug entry, closing regulatory loopholes used by big drug companies to block competition, and reforming specific practices of Pharmacy Benefit Managers (PBMs). Chairman Bernie Sanders, in his latest effort to hold Big Pharma accountable, also says he plans to call the chief executives of the world’s leading insulin manufacturers (Eli Lilly, Novo Nordisk, and Sanofi) to testify before the Committee. “Democrats continue to push measures to lower prices after passing legislation that allows Medicare to negotiate prices, penalizes price inflation, and caps seniors’ annual drug costs,” STAT reported. Keep it up, Congress – we look forward to fighting together for further reforms when you return from recess on Monday. — (Politico, Axios, STAT, STAT)
2. More Money In Patients’ Pockets Thanks To The Inflation Reduction Act
The Inflation Reduction Act is already helping millions of people on Medicare— and members of Congress are spreading the word. At a community center in Atlanta, Secretary of Health and Human Services Xavier Becerra and Senator Jon Ossoff highlighted how “a senior in Georgia will now save between $500 and $600 a year” because of the Inflation Reduction Act which “will also provide free vaccines to seniors for illnesses like the flu or shingles.” Congressman Ruben Gallego also celebrated that the new drug price law will help more than 28,000 Arizonians “save about $500 per year on their insulin,” and Senator Debbie Stabenow and Representative Hillary Scholten held a press conference in Grand Rapids, Michigan explaining the relief that the Inflation Reduction Act will provide for seniors. Looking ahead, the new law will continue to help more people on Medicare as the rest of the provisions are implemented. Yesterday, the Centers for Medicare and Medicaid Services (CMS) closed the public comment period on its March draft of the Medicare drug price negotiation program guidance and will release final guidance in July. The agency is focused on closing potential loopholes that drug companies could use to avoid negotiation. Not so fast pharma — CMS is making sure its new negotiation authority will bring as much benefit to patients in relation to as many drugs as possible. ? — (Cure Today, Coastal Point, 11alive, Forbes, Fox17, Reuters, Bloomberg)
3. No Innovation Found Here
In the latest example of drug company shady shenanigans, one biotech company is making millions price gouging patients without ever inventing a drug. Horizon Therapeutics, along with the previous manufacturers, raised the price of gout drug Krystexxa almost every year since it came to market. Without making any changes to improve the drug, the company now charges about 10 times as much as the price of the drug when it came to market in 2011 — so six months of treatment can currently be more than $400,000. Now, the company is cashing in again by selling to pharma giant Amgen. Tim Walbert, Horizon’s CEO, who will reportedly receive around $135 million when the deal closes, “has mastered a particular kind of industry expertise: taking drugs invented and tested by other people, wrapping them expertly in hard-nosed marketing and warm-hued patient relations, raising their prices, and enjoying astounding revenues,” KFF reported. Patients deserve investments in true innovation, not spending on marketing ploys on ineffective old drugs. — (KFF)
